November 15th, 2018

BioSystems Technology, BioVersys and Voxcan announce funding by Eurostars

BioSystems Technology, BioVersys and Voxcan announce funding for a total of about € 840’000, by Eurostars over a 3-year period for IMPACT2, a break-through innovative translational AMR platform that will expedite the development of novel new medicines in the fight against antimicrobial resistance.

Eurostars IMPACT2 PR 11.18

http://c1940652.r52.cf0.rackcdn.com/58528159b8d39a3eff000d0c/news1.jpg